Spots Global Cancer Trial Database for ql1706
Every month we try and update this database with for ql1706 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer | NCT05690945 | Lung Cancer | QL1706 Tilesizumab | 18 Years - 75 Years | Qilu Pharmaceutical Co., Ltd. | |
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | NCT05603039 | Advanced Liver ... | QL1706 QL1604 Bevacizumab | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | NCT05603039 | Advanced Liver ... | QL1706 QL1604 Bevacizumab | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | NCT05262413 | Advanced Renal ... | QL1706 Plus Len... | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | NCT05557565 | Cervical Cancer | QL1706 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients | NCT06313970 | Pancreatic Canc... | QL1706 Nab-paclitaxel Gemcitabine Bevacizumab | 18 Years - 75 Years | Fudan University | |
| A Study of QL1706 in Subjects With Advanced Malignant Tumor | NCT04296994 | Advanced Malign... | QL1706 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | NCT05329025 | Non-small-cell ... | QL1706 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | NCT05603039 | Advanced Liver ... | QL1706 QL1604 Bevacizumab | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | NCT05976568 | Hepatocellular ... | QL1706 Bevacizumab Oxaliplatin inj... Capecitabine Sintilimab | 18 Years - 75 Years | Qilu Pharmaceutical Co., Ltd. | |
| Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer | NCT05309629 | Extensive-stage... | QL1706 Carboplatin Etoposide | 18 Years - 75 Years | Qilu Pharmaceutical Co., Ltd. | |
| QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | NCT05799820 | Colorectal Carc... | QL1706 Bevacizumab Oxaliplatin inj... Capecitabine | 18 Years - 80 Years | Qilu Pharmaceutical Co., Ltd. | |
| A Phase II Study of CRT Combined With QL1706 in ESCC Patients | NCT05490719 | Esophageal Squa... | QL1706 | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | NCT05329025 | Non-small-cell ... | QL1706 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | NCT05976568 | Hepatocellular ... | QL1706 Bevacizumab Oxaliplatin inj... Capecitabine Sintilimab | 18 Years - 75 Years | Qilu Pharmaceutical Co., Ltd. | |
| A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | NCT05262413 | Advanced Renal ... | QL1706 Plus Len... | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients | NCT06313970 | Pancreatic Canc... | QL1706 Nab-paclitaxel Gemcitabine Bevacizumab | 18 Years - 75 Years | Fudan University | |
| Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer | NCT05309629 | Extensive-stage... | QL1706 Carboplatin Etoposide | 18 Years - 75 Years | Qilu Pharmaceutical Co., Ltd. | |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | NCT05576272 | Nasopharyngeal ... | QL1706 Carrelizumab Gemcitabine Cisplatin | 18 Years - | Qilu Pharmaceutical Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
